The Furoxan Nitric Oxide Donor, PRG150, Evokes Dose-Dependent Analgesia in a Rat Model of Painful Diabetic Neuropathy (PDN)

Huang, Lillian Y., Tsui, Debbie Y., Williams, Craig M., Wyse, Bruce D. and Smith, Maree T. (2015) The Furoxan Nitric Oxide Donor, PRG150, Evokes Dose-Dependent Analgesia in a Rat Model of Painful Diabetic Neuropathy (PDN). Clinical and Experimental Pharmacology and Physiology, 42 9: 921-929. doi:10.1111/1440-1681.12442


Author Huang, Lillian Y.
Tsui, Debbie Y.
Williams, Craig M.
Wyse, Bruce D.
Smith, Maree T.
Title The Furoxan Nitric Oxide Donor, PRG150, Evokes Dose-Dependent Analgesia in a Rat Model of Painful Diabetic Neuropathy (PDN)
Journal name Clinical and Experimental Pharmacology and Physiology   Check publisher's open access policy
ISSN 0305-1870
1440-1681
Publication date 2015-06-26
Year available 2015
Sub-type Article (original research)
DOI 10.1111/1440-1681.12442
Open Access Status Not Open Access
Volume 42
Issue 9
Start page 921
End page 929
Total pages 9
Place of publication Richmond, VIC Australia
Publisher Wiley-Blackwell Publishing Asia
Collection year 2016
Language eng
Formatted abstract
Painful diabetic neuropathy (PDN) is a type of peripheral neuropathic pain that is often intractable. Elevated nitric oxide (NO) from neuronal and non-neuronal sources in the somatosensory system is implicated in the pathobiology of peripheral neuropathic pain. However, in diabetes, nitrergic nerve degeneration to deplete NO bioactivity appears causal in the pathogenesis of irreversible autonomic neuropathy, another long term complication of diabetes. Hence, this study hypothesized that progressive NO depletion may underpin the pathobiology of PDN and that NO donors may alleviate PDN. Diabetes was induced in rats with intravenous streptozotocin (STZ) at 70 mg/kg and confirmed if blood glucose levels (BGLs) on day 10 post-STZ were ≥15 mmol/L. Analgesic efficacy of subcutaneous (s.c.) bolus doses of the furoxan NO donor, PRG150 was assessed in the STZ-diabetic rat model of PDN at 10-, 14- and 24-weeks post-STZ relative to the sydnominine NO donor, SIN-1 and its prodrug, molsidomine. PRG150 produced dose-dependent analgesia in STZ-diabetic rats whereas SIN-1 and molsidomine evoked neuro-excitatory side-effects, but not analgesia. The 1000-fold larger doses of PRG150 needed to produce analgesia at 14- and 24-weeks (800 pmol/kg) c.f. 10-weeks (8 fmol/kg) post-STZ in rats, suggest that progressive NO depletion is also causal in PDN. Importantly, doses of PRG150 up to 10 000 fold higher than the analgesic dose did not produce hypotension in rats. The 50-fold greater release of NO by SIN-1 c.f. PRG150 in vitro, may underpin the neuro-excitatory rather than analgesic effects of SIN-1/molsidomine. PRG150 is worthy of further investigation as a potential novel analgesic for PDN.
Keyword Painful diabetic neuropathy
Nitric oxide (NO)
Impaired NO bioactivity
NO donor
PRG 150
Nitroc oxide synthase (NOS)
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 3 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 4 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Sat, 27 Jun 2015, 15:29:44 EST by Professor Maree Smith on behalf of Centre for Integrated Preclinical Drug Development